Abbott Laboratories $ABT Shares Purchased by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP has increased its stake in Abbott Laboratories by 243.4%, owning 8,297 shares worth approximately $1.1 million as of its latest SEC filing.
• Abbott Laboratories reported $1.26 EPS this quarter, meeting analysts' estimates, with a 7.4% year-over-year revenue increase to $11.14 billion.
• The company has announced a quarterly dividend of $0.59, resulting in an annual yield of 1.8%.

Voleon Capital Management LP boosted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 243.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,297 shares of the healthcare product maker's stock after acquiring an additional 5,881 shares during the period. Voleon Capital Management LP's holdings in Abbott Laboratories were worth $1,101,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Hughes Financial Services LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at about $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories in the 1st quarter valued at about $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the 1st quarter worth approximately $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories during the 1st quarter worth approximately $33,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $132.27 on Tuesday. The business's 50 day simple moving average is $130.60 and its 200-day simple moving average is $131.36. The firm has a market capitalization of $230.21 billion, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company earned $1.14 EPS. Abbott Laboratories's revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were paid a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research report on Friday, July 18th. BTIG Research decreased their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research report on Friday, July 18th. Leerink Partners began coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 target price on the stock. Finally, Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price target for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus target price of $144.47.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.46% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.